holybun的个人主页 - 老虎社区

holybun

holybun

暂无个人介绍

IP属地：未知

2关注

1粉丝

0主题

0勋章

2021-12-22

I think he needs a new cfo, like like there's no financial planning within the company

Tesla's Musk says he sold 'enough stock'; slams California for 'overtaxation'

2021-12-21

Wow, just wow

Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study

2021-12-16

very nice

@MillionaireTiger:Pfizer Announced its Acquisition of Arena Pharmaceuticals in a $6.7 Billion

2021-12-15

I like what I'm seeing

Warren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4100142878992660","uuid":"4100142878992660","gmtCreate":1637039811799,"gmtModify":1640286010040,"name":"holybun","pinyin":"holybun","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":2,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.04.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.22","exceedPercentage":"93.88%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.17","exceedPercentage":"93.01%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":8,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691187998,"gmtCreate":1640150149936,"gmtModify":1640150150023,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"I think he needs a new cfo, like like there's no financial planning within the company","listText":"I think he needs a new cfo, like like there's no financial planning within the company","text":"I think he needs a new cfo, like like there's no financial planning within the company","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691187998","repostId":"2193167797","repostType":4,"repost":{"id":"2193167797","kind":"news","pubTimestamp":1640149696,"share":"https://www.laohu8.com/m/news/2193167797?lang=&edition=full","pubTime":"2021-12-22 13:08","market":"us","language":"en","title":"Tesla's Musk says he sold 'enough stock'; slams California for 'overtaxation'","url":"https://stock-news.laohu8.com/highlight/detail?id=2193167797","media":"StreetInsider","summary":"By Hyunjoo Jin\nSan Francisco (Reuters) - Tesla CEO Elon Musk said he had sold \"enough stock\" to reac","content":"<p><img src=\"https://static.tigerbbs.com/9efa7579eff10d0a2edd8fa3cf3fa5ad\" tg-width=\"200\" tg-height=\"133\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>By Hyunjoo Jin</p>\n<p>San Francisco (Reuters) - Tesla CEO Elon Musk said he had sold \"enough stock\" to reach his plan to sell 10% of his shares in the world's most valuable car company, according to an interview released on Tuesday.</p>\n<p>The billionaire, who moved the company's headquarters from California to Texas this month after his personal move last year, also slammed California for \"overtaxation.\"</p>\n<p>Tesla shares, which had hovered near record-highs, lost about a quarter of their value after Musk said on Nov. 6 he would sell 10% of his stake if <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> users agreed.</p>\n<p>On Tuesday, Musk sold another 583,611 shares, bringing the total number of shares he has offloaded to 13.5 million - about 80% of what he had planned to sell.</p>\n<p>\"I sold enough stock to get to around 10% plus the option exercise stuff and I tried to be extremely literal here,\" he said in the interview with satirical website Babylon Bee.</p>\n<p>When asked whether he sold the stock because of the Twitter poll, he said he needed to exercise stock options that are expiring next year \"no matter what.\" He also added that he sold an additional \"incremental stock\" to get near 10%.</p>\n<p>Out of the 13.5 million shares sold, 8.06 million were sold to pay taxes related to his options exercise.</p>\n<p>Musk said on Sunday on Twitter that he would pay more than $11 billion in taxes this year.</p>\n<p>\"California used to be the land of opportunity and now it is... becoming more so the land of sort of overregulation, overlitigation, overtaxation,\" he said, adding that it is \"increasingly difficult to get things done\" in California.</p>\n<p>(Reporting by Hyunjoo Jin. Editing by Gerry Doyle)</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla's Musk says he sold 'enough stock'; slams California for 'overtaxation'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla's Musk says he sold 'enough stock'; slams California for 'overtaxation'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 13:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19381699><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Hyunjoo Jin\nSan Francisco (Reuters) - Tesla CEO Elon Musk said he had sold \"enough stock\" to reach his plan to sell 10% of his shares in the world's most valuable car company, according to an ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19381699\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19381699","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193167797","content_text":"By Hyunjoo Jin\nSan Francisco (Reuters) - Tesla CEO Elon Musk said he had sold \"enough stock\" to reach his plan to sell 10% of his shares in the world's most valuable car company, according to an interview released on Tuesday.\nThe billionaire, who moved the company's headquarters from California to Texas this month after his personal move last year, also slammed California for \"overtaxation.\"\nTesla shares, which had hovered near record-highs, lost about a quarter of their value after Musk said on Nov. 6 he would sell 10% of his stake if Twitter users agreed.\nOn Tuesday, Musk sold another 583,611 shares, bringing the total number of shares he has offloaded to 13.5 million - about 80% of what he had planned to sell.\n\"I sold enough stock to get to around 10% plus the option exercise stuff and I tried to be extremely literal here,\" he said in the interview with satirical website Babylon Bee.\nWhen asked whether he sold the stock because of the Twitter poll, he said he needed to exercise stock options that are expiring next year \"no matter what.\" He also added that he sold an additional \"incremental stock\" to get near 10%.\nOut of the 13.5 million shares sold, 8.06 million were sold to pay taxes related to his options exercise.\nMusk said on Sunday on Twitter that he would pay more than $11 billion in taxes this year.\n\"California used to be the land of opportunity and now it is... becoming more so the land of sort of overregulation, overlitigation, overtaxation,\" he said, adding that it is \"increasingly difficult to get things done\" in California.\n(Reporting by Hyunjoo Jin. Editing by Gerry Doyle)","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693778284,"gmtCreate":1640090951437,"gmtModify":1640090951437,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"Wow, just wow","listText":"Wow, just wow","text":"Wow, just wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693778284","repostId":"1148289841","repostType":4,"repost":{"id":"1148289841","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640085374,"share":"https://www.laohu8.com/m/news/1148289841?lang=&edition=full","pubTime":"2021-12-21 19:16","market":"us","language":"en","title":"Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1148289841","media":"Benzinga","summary":"Aldeyra Therapeutics Inc reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalm","content":"<p><b>Aldeyra Therapeutics Inc</b>&nbsp;reported topline data&nbsp;from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease.</p>\n<ul>\n <li>The trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.</li>\n <li>Statistical significance was also achieved for the post-hoc assessment of Schirmer test responders of over 10 mm.</li>\n <li>The primary endpoint of the upcoming Phase 3 TRANQUILITY-2 trial has been modified such that the endpoint will have been met if either the Schirmer test or ocular redness demonstrates statistical significance.</li>\n <li>In addition, target enrollment in TRANQUILITY-2 has been increased from 300 to up to 400 patients. The company expects topline results in mid-2022.</li>\n <li>The company intends to file the marketing application for dry eye disease indication in mid-2022.</li>\n <li>Application for allergic conjunctivitis, another proposed indication, is expected to occur after the dry eye disease submission and following completion of an additional allergen chamber trial requested by the FDA.</li>\n <li>No safety signals were observed, and reproxalap was well tolerated; there were no treatment-related discontinuations or moderate or severe adverse events.</li>\n <li><b>Price Action:</b>&nbsp;ALDX shares are down 38.29% at $4.4 during the premarket session on the last check Tuesday.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/b2918c536ca5a074f762901ace4764fc\" tg-width=\"710\" tg-height=\"614\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-21 19:16</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Aldeyra Therapeutics Inc</b>&nbsp;reported topline data&nbsp;from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease.</p>\n<ul>\n <li>The trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.</li>\n <li>Statistical significance was also achieved for the post-hoc assessment of Schirmer test responders of over 10 mm.</li>\n <li>The primary endpoint of the upcoming Phase 3 TRANQUILITY-2 trial has been modified such that the endpoint will have been met if either the Schirmer test or ocular redness demonstrates statistical significance.</li>\n <li>In addition, target enrollment in TRANQUILITY-2 has been increased from 300 to up to 400 patients. The company expects topline results in mid-2022.</li>\n <li>The company intends to file the marketing application for dry eye disease indication in mid-2022.</li>\n <li>Application for allergic conjunctivitis, another proposed indication, is expected to occur after the dry eye disease submission and following completion of an additional allergen chamber trial requested by the FDA.</li>\n <li>No safety signals were observed, and reproxalap was well tolerated; there were no treatment-related discontinuations or moderate or severe adverse events.</li>\n <li><b>Price Action:</b>&nbsp;ALDX shares are down 38.29% at $4.4 during the premarket session on the last check Tuesday.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/b2918c536ca5a074f762901ace4764fc\" tg-width=\"710\" tg-height=\"614\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148289841","content_text":"Aldeyra Therapeutics Inc reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease.\n\nThe trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.\nStatistical significance was also achieved for the post-hoc assessment of Schirmer test responders of over 10 mm.\nThe primary endpoint of the upcoming Phase 3 TRANQUILITY-2 trial has been modified such that the endpoint will have been met if either the Schirmer test or ocular redness demonstrates statistical significance.\nIn addition, target enrollment in TRANQUILITY-2 has been increased from 300 to up to 400 patients. The company expects topline results in mid-2022.\nThe company intends to file the marketing application for dry eye disease indication in mid-2022.\nApplication for allergic conjunctivitis, another proposed indication, is expected to occur after the dry eye disease submission and following completion of an additional allergen chamber trial requested by the FDA.\nNo safety signals were observed, and reproxalap was well tolerated; there were no treatment-related discontinuations or moderate or severe adverse events.\nPrice Action: ALDX shares are down 38.29% at $4.4 during the premarket session on the last check Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":483,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690959006,"gmtCreate":1639624289105,"gmtModify":1639624315784,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"very nice","listText":"very nice","text":"very nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690959006","repostId":"607944827","repostType":1,"repost":{"id":607944827,"gmtCreate":1639481361363,"gmtModify":1639504322704,"author":{"id":"3527667618821228","authorId":"3527667618821228","name":"MillionaireTiger","avatar":"https://static.tigerbbs.com/8901a3026957857b6996ae953d595bee","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667618821228","idStr":"3527667618821228"},"themes":[],"title":"Pfizer Announced its Acquisition of Arena Pharmaceuticals in a $6.7 Billion","htmlText":"Hey&nbsp;Tigers! Do&nbsp;you&nbsp;notice&nbsp;Pfizer's&nbsp;new&nbsp;play? Pfizer&nbsp;announced its&nbsp;acquisition&nbsp;of&nbsp;Arena Pharmaceuticals&nbsp;today in a&nbsp;$6.7 billion deal&nbsp;for the company’s research on inflammatory conditions affecting the stomach and intestine.&nbsp;Pfizer will pay Arena $100/share in cash. Shares of Arena stock nearly&nbsp;doubled&nbsp;yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions. Pfizer is on a roll, lately. In addition to the o","listText":"Hey&nbsp;Tigers! Do&nbsp;you&nbsp;notice&nbsp;Pfizer's&nbsp;new&nbsp;play? Pfizer&nbsp;announced its&nbsp;acquisition&nbsp;of&nbsp;Arena Pharmaceuticals&nbsp;today in a&nbsp;$6.7 billion deal&nbsp;for the company’s research on inflammatory conditions affecting the stomach and intestine.&nbsp;Pfizer will pay Arena $100/share in cash. Shares of Arena stock nearly&nbsp;doubled&nbsp;yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions. Pfizer is on a roll, lately. In addition to the o","text":"Hey Tigers! Do you notice Pfizer's new play? Pfizer announced its acquisition of Arena Pharmaceuticals today in a $6.7 billion deal for the company’s research on inflammatory conditions affecting the stomach and intestine. Pfizer will pay Arena $100/share in cash. Shares of Arena stock nearly doubled yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions. Pfizer is on a roll, lately. In addition to the o","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607944827","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607232042,"gmtCreate":1639543357033,"gmtModify":1639543357033,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"I like what I'm seeing","listText":"I like what I'm seeing","text":"I like what I'm seeing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607232042","repostId":"1156446659","repostType":4,"repost":{"id":"1156446659","kind":"news","pubTimestamp":1639540344,"share":"https://www.laohu8.com/m/news/1156446659?lang=&edition=full","pubTime":"2021-12-15 11:52","market":"us","language":"en","title":"Warren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap","url":"https://stock-news.laohu8.com/highlight/detail?id=1156446659","media":"Business Insider","summary":"Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Frid","content":"<ul>\n <li><b>Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Friday.</b></li>\n <li><b>That makes the stake worth half of Berkshire's entire equity portfolio, and almost 25% of its $649 billion market capitalization.</b></li>\n <li><b>Warren Buffett started to build Berkshire's position in Apple in 2016 and added to it up until mid-2018.</b></li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4348b5dc216a2be5e154d22e356336b9\" tg-width=\"790\" tg-height=\"395\" width=\"100%\" height=\"auto\"><span>SCOTT MORGAN/REUTERS</span></p>\n<p>Warren Buffett is known for concentrating his investments to build generational wealth, and&nbsp;Berkshire Hathaway's&nbsp;stake in&nbsp;Apple&nbsp;is no better example of that investment practice.</p>\n<p>Berkshire's 887.1 million shares in the iPhone maker swelled to a record value of $159 billion on Friday, a 342% increase from its&nbsp;original cost basis of about $36 billion.That means Apple is now worth more than half of Berkshire's $293 billion equity portfolio, based on data from its third-quarter 13F filing.</p>\n<p>And assuming Berkshire hasn't trimmed its Apple position since September 30, the equity stake now represents about a quarter of Berkshire Hathaway's $649 billion market capitalization.</p>\n<p>What also makes Buffett's concentration in Apple notable is that it didn't take&nbsp;decades to compound&nbsp;like most successful investments managed by Buffett. Instead, it's only been five years since Berkshire began to build its stake in Apple.</p>\n<p>The conglomerate first purchased Apple shares in 2016 and continued buying them until mid-2018, when the position topped 1 billion shares after adjusting for a 4-for-1 stock split in 2020. Buffett has&nbsp;trimmed Berkshire's position in Apple&nbsp;by about 12% since initially building the stake.</p>\n<p>Barring any changes since the most recent 13F filing, Berkshire's stock portfolio would be up 13.9% quarter-to-date, according to&nbsp;an analysis by Bespoke.Much of that gain has been driven by Apple's quarter-to-date gain of more than 20%.</p>\n<p>Year-to-date, Apple is up 31%, compared to Berkshire Hathaway's return of 26%. Apple's stock price was less than&nbsp;$1.00 away from hitting a $3 trillion valuation on Monday.</p>\n<p>Berkshire's three largest positions after Apple are&nbsp;Bank of America,American Express, and&nbsp;Coca-Cola, which make up a combined 30% of the equity portfolio's value. And Berkshire is still sitting on about $150 billion in cash that it has yet to put to work.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Warren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWarren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-15 11:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://markets.businessinsider.com/news/stocks/warren-buffett-apple-stake-half-berkshire-hathaway-equity-portfolio-concentration-2021-12><strong>Business Insider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Friday.\nThat makes the stake worth half of Berkshire's entire equity portfolio, and almost 25% of its $...</p>\n\n<a href=\"https://markets.businessinsider.com/news/stocks/warren-buffett-apple-stake-half-berkshire-hathaway-equity-portfolio-concentration-2021-12\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","AAPL":"苹果","BRK.A":"伯克希尔"},"source_url":"https://markets.businessinsider.com/news/stocks/warren-buffett-apple-stake-half-berkshire-hathaway-equity-portfolio-concentration-2021-12","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156446659","content_text":"Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Friday.\nThat makes the stake worth half of Berkshire's entire equity portfolio, and almost 25% of its $649 billion market capitalization.\nWarren Buffett started to build Berkshire's position in Apple in 2016 and added to it up until mid-2018.\n\nSCOTT MORGAN/REUTERS\nWarren Buffett is known for concentrating his investments to build generational wealth, and Berkshire Hathaway's stake in Apple is no better example of that investment practice.\nBerkshire's 887.1 million shares in the iPhone maker swelled to a record value of $159 billion on Friday, a 342% increase from its original cost basis of about $36 billion.That means Apple is now worth more than half of Berkshire's $293 billion equity portfolio, based on data from its third-quarter 13F filing.\nAnd assuming Berkshire hasn't trimmed its Apple position since September 30, the equity stake now represents about a quarter of Berkshire Hathaway's $649 billion market capitalization.\nWhat also makes Buffett's concentration in Apple notable is that it didn't take decades to compound like most successful investments managed by Buffett. Instead, it's only been five years since Berkshire began to build its stake in Apple.\nThe conglomerate first purchased Apple shares in 2016 and continued buying them until mid-2018, when the position topped 1 billion shares after adjusting for a 4-for-1 stock split in 2020. Buffett has trimmed Berkshire's position in Apple by about 12% since initially building the stake.\nBarring any changes since the most recent 13F filing, Berkshire's stock portfolio would be up 13.9% quarter-to-date, according to an analysis by Bespoke.Much of that gain has been driven by Apple's quarter-to-date gain of more than 20%.\nYear-to-date, Apple is up 31%, compared to Berkshire Hathaway's return of 26%. Apple's stock price was less than $1.00 away from hitting a $3 trillion valuation on Monday.\nBerkshire's three largest positions after Apple are Bank of America,American Express, and Coca-Cola, which make up a combined 30% of the equity portfolio's value. And Berkshire is still sitting on about $150 billion in cash that it has yet to put to work.","news_type":1},"isVote":1,"tweetType":1,"viewCount":784,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":607232042,"gmtCreate":1639543357033,"gmtModify":1639543357033,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"I like what I'm seeing","listText":"I like what I'm seeing","text":"I like what I'm seeing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607232042","repostId":"1156446659","repostType":4,"repost":{"id":"1156446659","kind":"news","pubTimestamp":1639540344,"share":"https://www.laohu8.com/m/news/1156446659?lang=&edition=full","pubTime":"2021-12-15 11:52","market":"us","language":"en","title":"Warren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap","url":"https://stock-news.laohu8.com/highlight/detail?id=1156446659","media":"Business Insider","summary":"Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Frid","content":"<ul>\n <li><b>Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Friday.</b></li>\n <li><b>That makes the stake worth half of Berkshire's entire equity portfolio, and almost 25% of its $649 billion market capitalization.</b></li>\n <li><b>Warren Buffett started to build Berkshire's position in Apple in 2016 and added to it up until mid-2018.</b></li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4348b5dc216a2be5e154d22e356336b9\" tg-width=\"790\" tg-height=\"395\" width=\"100%\" height=\"auto\"><span>SCOTT MORGAN/REUTERS</span></p>\n<p>Warren Buffett is known for concentrating his investments to build generational wealth, and&nbsp;Berkshire Hathaway's&nbsp;stake in&nbsp;Apple&nbsp;is no better example of that investment practice.</p>\n<p>Berkshire's 887.1 million shares in the iPhone maker swelled to a record value of $159 billion on Friday, a 342% increase from its&nbsp;original cost basis of about $36 billion.That means Apple is now worth more than half of Berkshire's $293 billion equity portfolio, based on data from its third-quarter 13F filing.</p>\n<p>And assuming Berkshire hasn't trimmed its Apple position since September 30, the equity stake now represents about a quarter of Berkshire Hathaway's $649 billion market capitalization.</p>\n<p>What also makes Buffett's concentration in Apple notable is that it didn't take&nbsp;decades to compound&nbsp;like most successful investments managed by Buffett. Instead, it's only been five years since Berkshire began to build its stake in Apple.</p>\n<p>The conglomerate first purchased Apple shares in 2016 and continued buying them until mid-2018, when the position topped 1 billion shares after adjusting for a 4-for-1 stock split in 2020. Buffett has&nbsp;trimmed Berkshire's position in Apple&nbsp;by about 12% since initially building the stake.</p>\n<p>Barring any changes since the most recent 13F filing, Berkshire's stock portfolio would be up 13.9% quarter-to-date, according to&nbsp;an analysis by Bespoke.Much of that gain has been driven by Apple's quarter-to-date gain of more than 20%.</p>\n<p>Year-to-date, Apple is up 31%, compared to Berkshire Hathaway's return of 26%. Apple's stock price was less than&nbsp;$1.00 away from hitting a $3 trillion valuation on Monday.</p>\n<p>Berkshire's three largest positions after Apple are&nbsp;Bank of America,American Express, and&nbsp;Coca-Cola, which make up a combined 30% of the equity portfolio's value. And Berkshire is still sitting on about $150 billion in cash that it has yet to put to work.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Warren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWarren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-15 11:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://markets.businessinsider.com/news/stocks/warren-buffett-apple-stake-half-berkshire-hathaway-equity-portfolio-concentration-2021-12><strong>Business Insider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Friday.\nThat makes the stake worth half of Berkshire's entire equity portfolio, and almost 25% of its $...</p>\n\n<a href=\"https://markets.businessinsider.com/news/stocks/warren-buffett-apple-stake-half-berkshire-hathaway-equity-portfolio-concentration-2021-12\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","AAPL":"苹果","BRK.A":"伯克希尔"},"source_url":"https://markets.businessinsider.com/news/stocks/warren-buffett-apple-stake-half-berkshire-hathaway-equity-portfolio-concentration-2021-12","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156446659","content_text":"Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Friday.\nThat makes the stake worth half of Berkshire's entire equity portfolio, and almost 25% of its $649 billion market capitalization.\nWarren Buffett started to build Berkshire's position in Apple in 2016 and added to it up until mid-2018.\n\nSCOTT MORGAN/REUTERS\nWarren Buffett is known for concentrating his investments to build generational wealth, and Berkshire Hathaway's stake in Apple is no better example of that investment practice.\nBerkshire's 887.1 million shares in the iPhone maker swelled to a record value of $159 billion on Friday, a 342% increase from its original cost basis of about $36 billion.That means Apple is now worth more than half of Berkshire's $293 billion equity portfolio, based on data from its third-quarter 13F filing.\nAnd assuming Berkshire hasn't trimmed its Apple position since September 30, the equity stake now represents about a quarter of Berkshire Hathaway's $649 billion market capitalization.\nWhat also makes Buffett's concentration in Apple notable is that it didn't take decades to compound like most successful investments managed by Buffett. Instead, it's only been five years since Berkshire began to build its stake in Apple.\nThe conglomerate first purchased Apple shares in 2016 and continued buying them until mid-2018, when the position topped 1 billion shares after adjusting for a 4-for-1 stock split in 2020. Buffett has trimmed Berkshire's position in Apple by about 12% since initially building the stake.\nBarring any changes since the most recent 13F filing, Berkshire's stock portfolio would be up 13.9% quarter-to-date, according to an analysis by Bespoke.Much of that gain has been driven by Apple's quarter-to-date gain of more than 20%.\nYear-to-date, Apple is up 31%, compared to Berkshire Hathaway's return of 26%. Apple's stock price was less than $1.00 away from hitting a $3 trillion valuation on Monday.\nBerkshire's three largest positions after Apple are Bank of America,American Express, and Coca-Cola, which make up a combined 30% of the equity portfolio's value. And Berkshire is still sitting on about $150 billion in cash that it has yet to put to work.","news_type":1},"isVote":1,"tweetType":1,"viewCount":784,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693778284,"gmtCreate":1640090951437,"gmtModify":1640090951437,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"Wow, just wow","listText":"Wow, just wow","text":"Wow, just wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693778284","repostId":"1148289841","repostType":4,"repost":{"id":"1148289841","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640085374,"share":"https://www.laohu8.com/m/news/1148289841?lang=&edition=full","pubTime":"2021-12-21 19:16","market":"us","language":"en","title":"Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1148289841","media":"Benzinga","summary":"Aldeyra Therapeutics Inc reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalm","content":"<p><b>Aldeyra Therapeutics Inc</b>&nbsp;reported topline data&nbsp;from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease.</p>\n<ul>\n <li>The trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.</li>\n <li>Statistical significance was also achieved for the post-hoc assessment of Schirmer test responders of over 10 mm.</li>\n <li>The primary endpoint of the upcoming Phase 3 TRANQUILITY-2 trial has been modified such that the endpoint will have been met if either the Schirmer test or ocular redness demonstrates statistical significance.</li>\n <li>In addition, target enrollment in TRANQUILITY-2 has been increased from 300 to up to 400 patients. The company expects topline results in mid-2022.</li>\n <li>The company intends to file the marketing application for dry eye disease indication in mid-2022.</li>\n <li>Application for allergic conjunctivitis, another proposed indication, is expected to occur after the dry eye disease submission and following completion of an additional allergen chamber trial requested by the FDA.</li>\n <li>No safety signals were observed, and reproxalap was well tolerated; there were no treatment-related discontinuations or moderate or severe adverse events.</li>\n <li><b>Price Action:</b>&nbsp;ALDX shares are down 38.29% at $4.4 during the premarket session on the last check Tuesday.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/b2918c536ca5a074f762901ace4764fc\" tg-width=\"710\" tg-height=\"614\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-21 19:16</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Aldeyra Therapeutics Inc</b>&nbsp;reported topline data&nbsp;from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease.</p>\n<ul>\n <li>The trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.</li>\n <li>Statistical significance was also achieved for the post-hoc assessment of Schirmer test responders of over 10 mm.</li>\n <li>The primary endpoint of the upcoming Phase 3 TRANQUILITY-2 trial has been modified such that the endpoint will have been met if either the Schirmer test or ocular redness demonstrates statistical significance.</li>\n <li>In addition, target enrollment in TRANQUILITY-2 has been increased from 300 to up to 400 patients. The company expects topline results in mid-2022.</li>\n <li>The company intends to file the marketing application for dry eye disease indication in mid-2022.</li>\n <li>Application for allergic conjunctivitis, another proposed indication, is expected to occur after the dry eye disease submission and following completion of an additional allergen chamber trial requested by the FDA.</li>\n <li>No safety signals were observed, and reproxalap was well tolerated; there were no treatment-related discontinuations or moderate or severe adverse events.</li>\n <li><b>Price Action:</b>&nbsp;ALDX shares are down 38.29% at $4.4 during the premarket session on the last check Tuesday.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/b2918c536ca5a074f762901ace4764fc\" tg-width=\"710\" tg-height=\"614\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148289841","content_text":"Aldeyra Therapeutics Inc reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease.\n\nThe trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.\nStatistical significance was also achieved for the post-hoc assessment of Schirmer test responders of over 10 mm.\nThe primary endpoint of the upcoming Phase 3 TRANQUILITY-2 trial has been modified such that the endpoint will have been met if either the Schirmer test or ocular redness demonstrates statistical significance.\nIn addition, target enrollment in TRANQUILITY-2 has been increased from 300 to up to 400 patients. The company expects topline results in mid-2022.\nThe company intends to file the marketing application for dry eye disease indication in mid-2022.\nApplication for allergic conjunctivitis, another proposed indication, is expected to occur after the dry eye disease submission and following completion of an additional allergen chamber trial requested by the FDA.\nNo safety signals were observed, and reproxalap was well tolerated; there were no treatment-related discontinuations or moderate or severe adverse events.\nPrice Action: ALDX shares are down 38.29% at $4.4 during the premarket session on the last check Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":483,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691187998,"gmtCreate":1640150149936,"gmtModify":1640150150023,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"I think he needs a new cfo, like like there's no financial planning within the company","listText":"I think he needs a new cfo, like like there's no financial planning within the company","text":"I think he needs a new cfo, like like there's no financial planning within the company","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691187998","repostId":"2193167797","repostType":4,"repost":{"id":"2193167797","kind":"news","pubTimestamp":1640149696,"share":"https://www.laohu8.com/m/news/2193167797?lang=&edition=full","pubTime":"2021-12-22 13:08","market":"us","language":"en","title":"Tesla's Musk says he sold 'enough stock'; slams California for 'overtaxation'","url":"https://stock-news.laohu8.com/highlight/detail?id=2193167797","media":"StreetInsider","summary":"By Hyunjoo Jin\nSan Francisco (Reuters) - Tesla CEO Elon Musk said he had sold \"enough stock\" to reac","content":"<p><img src=\"https://static.tigerbbs.com/9efa7579eff10d0a2edd8fa3cf3fa5ad\" tg-width=\"200\" tg-height=\"133\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>By Hyunjoo Jin</p>\n<p>San Francisco (Reuters) - Tesla CEO Elon Musk said he had sold \"enough stock\" to reach his plan to sell 10% of his shares in the world's most valuable car company, according to an interview released on Tuesday.</p>\n<p>The billionaire, who moved the company's headquarters from California to Texas this month after his personal move last year, also slammed California for \"overtaxation.\"</p>\n<p>Tesla shares, which had hovered near record-highs, lost about a quarter of their value after Musk said on Nov. 6 he would sell 10% of his stake if <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> users agreed.</p>\n<p>On Tuesday, Musk sold another 583,611 shares, bringing the total number of shares he has offloaded to 13.5 million - about 80% of what he had planned to sell.</p>\n<p>\"I sold enough stock to get to around 10% plus the option exercise stuff and I tried to be extremely literal here,\" he said in the interview with satirical website Babylon Bee.</p>\n<p>When asked whether he sold the stock because of the Twitter poll, he said he needed to exercise stock options that are expiring next year \"no matter what.\" He also added that he sold an additional \"incremental stock\" to get near 10%.</p>\n<p>Out of the 13.5 million shares sold, 8.06 million were sold to pay taxes related to his options exercise.</p>\n<p>Musk said on Sunday on Twitter that he would pay more than $11 billion in taxes this year.</p>\n<p>\"California used to be the land of opportunity and now it is... becoming more so the land of sort of overregulation, overlitigation, overtaxation,\" he said, adding that it is \"increasingly difficult to get things done\" in California.</p>\n<p>(Reporting by Hyunjoo Jin. Editing by Gerry Doyle)</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla's Musk says he sold 'enough stock'; slams California for 'overtaxation'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla's Musk says he sold 'enough stock'; slams California for 'overtaxation'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 13:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19381699><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Hyunjoo Jin\nSan Francisco (Reuters) - Tesla CEO Elon Musk said he had sold \"enough stock\" to reach his plan to sell 10% of his shares in the world's most valuable car company, according to an ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19381699\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19381699","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193167797","content_text":"By Hyunjoo Jin\nSan Francisco (Reuters) - Tesla CEO Elon Musk said he had sold \"enough stock\" to reach his plan to sell 10% of his shares in the world's most valuable car company, according to an interview released on Tuesday.\nThe billionaire, who moved the company's headquarters from California to Texas this month after his personal move last year, also slammed California for \"overtaxation.\"\nTesla shares, which had hovered near record-highs, lost about a quarter of their value after Musk said on Nov. 6 he would sell 10% of his stake if Twitter users agreed.\nOn Tuesday, Musk sold another 583,611 shares, bringing the total number of shares he has offloaded to 13.5 million - about 80% of what he had planned to sell.\n\"I sold enough stock to get to around 10% plus the option exercise stuff and I tried to be extremely literal here,\" he said in the interview with satirical website Babylon Bee.\nWhen asked whether he sold the stock because of the Twitter poll, he said he needed to exercise stock options that are expiring next year \"no matter what.\" He also added that he sold an additional \"incremental stock\" to get near 10%.\nOut of the 13.5 million shares sold, 8.06 million were sold to pay taxes related to his options exercise.\nMusk said on Sunday on Twitter that he would pay more than $11 billion in taxes this year.\n\"California used to be the land of opportunity and now it is... becoming more so the land of sort of overregulation, overlitigation, overtaxation,\" he said, adding that it is \"increasingly difficult to get things done\" in California.\n(Reporting by Hyunjoo Jin. Editing by Gerry Doyle)","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690959006,"gmtCreate":1639624289105,"gmtModify":1639624315784,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"very nice","listText":"very nice","text":"very nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690959006","repostId":"607944827","repostType":1,"repost":{"id":607944827,"gmtCreate":1639481361363,"gmtModify":1639504322704,"author":{"id":"3527667618821228","authorId":"3527667618821228","name":"MillionaireTiger","avatar":"https://static.tigerbbs.com/8901a3026957857b6996ae953d595bee","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667618821228","idStr":"3527667618821228"},"themes":[],"title":"Pfizer Announced its Acquisition of Arena Pharmaceuticals in a $6.7 Billion","htmlText":"Hey&nbsp;Tigers! Do&nbsp;you&nbsp;notice&nbsp;Pfizer's&nbsp;new&nbsp;play? Pfizer&nbsp;announced its&nbsp;acquisition&nbsp;of&nbsp;Arena Pharmaceuticals&nbsp;today in a&nbsp;$6.7 billion deal&nbsp;for the company’s research on inflammatory conditions affecting the stomach and intestine.&nbsp;Pfizer will pay Arena $100/share in cash. Shares of Arena stock nearly&nbsp;doubled&nbsp;yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions. Pfizer is on a roll, lately. In addition to the o","listText":"Hey&nbsp;Tigers! Do&nbsp;you&nbsp;notice&nbsp;Pfizer's&nbsp;new&nbsp;play? Pfizer&nbsp;announced its&nbsp;acquisition&nbsp;of&nbsp;Arena Pharmaceuticals&nbsp;today in a&nbsp;$6.7 billion deal&nbsp;for the company’s research on inflammatory conditions affecting the stomach and intestine.&nbsp;Pfizer will pay Arena $100/share in cash. Shares of Arena stock nearly&nbsp;doubled&nbsp;yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions. Pfizer is on a roll, lately. In addition to the o","text":"Hey Tigers! Do you notice Pfizer's new play? Pfizer announced its acquisition of Arena Pharmaceuticals today in a $6.7 billion deal for the company’s research on inflammatory conditions affecting the stomach and intestine. Pfizer will pay Arena $100/share in cash. Shares of Arena stock nearly doubled yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions. Pfizer is on a roll, lately. In addition to the o","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607944827","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}